Bitter Melon extract (BME) kills breast, colon, ovarian, pancreatic, liver, head and neck, and probably other cancers too. More importantly, Bitter Melon extract enhances the efficacy of certain chemotherapeutic agents. Please refer to the studies linked below.
Since the founding of PeopleBeatingCancer in 2004, it has become increasingly clear to me that toxic therapies lose their efficacy while causing short, long-term and late-stage side effects.
In short, cancer patients need help if they exclusively focus on chemotherapy and/or radiation. Bitter melon extract is just the kind of support that cancer patients need.
Is the information linked and excerpted below “clinical controlled” evidence? No. But the evidence-based research below clearly indicates that Bitter Melon extract may play a significant role in managing your cancer.
I was diagnosed with an “incurable” blood cancer, multiple myeloma, in 1994. Aggressive conventional therapies did little for me. I have been living in complete remission from my incurable cancer since April of 1999 by living an evidence-based, non-toxic, anti-cancer lifestyle through nutrition, supplementation, bone health, detoxification, and more.
I am both a cancer survivor and cancer coach. For more information about non-conventional therapies for your cancer scroll down the page, post a question and I will reply ASAP.
“Conclusion. BME functions as a natural AMPK activator in the inhibition of ovarian cancer cell growth and might be useful as a supplement to improve the efficacy of cisplatin-based chemotherapy in ovarian cancer.”
“A new study shows that bitter melon juice restricts the ability of pancreatic cancer cells to metabolize glucose, thus cutting the cells’ energy source and eventually killing them…”
“Our data show that the natural compound MCL manifests antitumor activities towards HCC and therefore suggest MCL as a promising chemotherapeutic agent.”
” We also observed that BME treatment in HNSCC reduced phosphoStat3, c-myc and Mcl-1 expression, downstream signaling molecules of c-Met. Furthermore, BME treatment in HNSCC cells modulated the expression of key cell cycle progression molecules leading to halted cell growth…”
“Here, we determined BME effects on anticancer activity and bioavailability of doxorubicin (DOX) in colon cancer cells. BME enhanced the effect of DOX on cell proliferation and sensitized the cells toward DOX upon pretreatment. Furthermore, there was both increased drug uptake and reduced drug efflux. We also observed a reduction in the expression of multidrug resistance conferring proteins (MDRCP) P-glycoprotein, MRP-2, and BCRP…”